This article was downloaded by: [Princeton University] On: 08 October 2013, At: 20:00 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Carbohydrate Chemistry

Publication details, including instructions for authors and subscription information: <u>http://www.tandfonline.com/loi/lcar20</u>

SYNTHESIS OF O-METHYLATED DISACCHARIDES RELATED TO EXCRETORY/ SECRETORY ANTIGENS OF TOXOCARA LARVAE

Hassan Amer^a, Andreas Hofinger^a, Michael Puchberger^a & Paul Kosma^b

^a Institut für Chemie, Universität für Bodenkultur, Muthgasse 18, Wien, A-1190, Austria ^b Institut für Chemie, Universität für Bodenkultur, Muthgasse 18, Wien, A-1190, Austria Published online: 16 Aug 2006.

To cite this article: Hassan Amer , Andreas Hofinger , Michael Puchberger & Paul Kosma (2001) SYNTHESIS OF O-METHYLATED DISACCHARIDES RELATED TO EXCRETORY/ SECRETORY ANTIGENS OF TOXOCARA LARVAE , Journal of Carbohydrate Chemistry, 20:7-8, 719-731

To link to this article: http://dx.doi.org/10.1081/CAR-100108285

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions

J. CARBOHYDRATE CHEMISTRY, 20(7&8), 719–731 (2001)

SYNTHESIS OF *O*-METHYLATED DISACCHARIDES RELATED TO EXCRETORY/ SECRETORY ANTIGENS OF *TOXOCARA* LARVAE¹

Hassan Amer, Andreas Hofinger, Michael Puchberger, and Paul Kosma*

Institut für Chemie, Universität für Bodenkultur, Muthgasse 18, A-1190 Wien, Austria

ABSTRACT

The disaccharides 2-O-Me- α -L-Fucp-(1 \rightarrow 2)- β -D-Galp-(1 \rightarrow OAllyl) **12**, α -L-Fucp-(1 \rightarrow 2)-4-O-Me- β -D-Galp-(1 \rightarrow OAllyl) **15**, and 2-O-Me- α -L-Fucp-(1 \rightarrow 2)-4-O-Me- β -D-Galp-(1 \rightarrow OAllyl) **18** have been synthesized. Glycosylation reactions were performed using ethyl 1-thiofucopyranosides as glycosyl donors and *N*-iodosuccinimide-triflic acid as the activating agent. The *O*-methylated disaccharides correspond to highly immunogenic *O*-glycan antigens occurring at the surface of *Toxocara canis* and *Toxocara cati* larvae.

INTRODUCTION

Toxocara canis and Toxocara cati are parasitic roundworms usually occurring in dogs and cats, which may cause severe infections in a human host affecting eyes, liver and the central nervous system.² The surface coat of the parasitic nematode larvae represents the major immunological challenge to the host immune system.³ In particular, glycoproteins being present in multiple copies at the outer layer elicit a strong immune response, are subsequently released from the surface and divert the immune attack from the mobile nematode. The structure of the excreted and secreted glycoproteins (TES antigens) from Toxocara canis investigated by MS analysis of alditol acetates revealed the presence of the trisaccharide backbone α -L-Fucp-(1 \rightarrow 2)- β -D-Galp-(1 \rightarrow 3)-D-GalpNAc.⁴ The fucose part has been found to be *O*-methylated at the 2-position. In addition, \sim 50% of the glycans

ORDER		REPRINTS
-------	--	----------

contained a 4-*O*-methyl group at the galactopyranosyl unit, which is also the prominent structure found in *T. cati* glycans. The anomeric configuration of the Gal*p*NAc residue has yet to be elucidated. Monoclonal anti-carbohydrate antibodies which have been raised against the TES antigens bind to different sites within the larval parasite.⁵ For a detailed immunochemical characterization of those monoclonal antibodies, we have synthesized three potential carbohydrate ligands which are *O*-methylated either at position 2 of the fucopyranosyl moiety or at position 4 of the galactopyranosyl unit or at both positions. Herein we report on the synthesis of the corresponding disaccharide allyl glycosides, which may be converted into spacer-elongated derivatives to be coupled to proteins.⁶

RESULTS AND DISCUSSION

For the synthesis of the allyl galactopyranoside acceptor derivatives, the known⁷ allyl β -D-galactopyranoside **1** was reacted with anisaldehyde dimethyl acetal in the presence of *p*-toluenesulphonic acid in MeCN to give the crystalline 4,6-*O-p*-methoxybenzylidene derivative **2** in 81% yield.⁸ Regioselective protection of the 3-OH group was achieved in 77% yield by reaction of the 2,3-*O*-dibutylstannylene intermediate with *p*-methoxybenzyl chloride / tetra-*n*-butylammonium iodide⁹ to furnish the acceptor **3**.

For the subsequent introduction of the 4-*O*-methyl group, compound **3** was *O*-acetylated with acetic anhydride / pyridine to afford compound **4** in 92% yield. The ¹H NMR spectrum of **4** displayed a downfield shift for H-2 to 5.36 ppm, thereby confirming the structural assignment of the 3-*O*-*p*-methoxybenzyl substituent. Reductive ring opening of the benzylidene acetal¹⁰ using NaCNBH₃ / trifluoroacetic acid in DMF furnished the 6-*O*-*p*-methoxybenzyl ether derivative **5** in 70% yield and the 4-*O*-*p*-methoxybenzyl isomer in 20% yield. Methylation of **5** was performed with MeI / NaH in DMF to give compound **6** in 87% yield. Removal of the 2-*O*-acetyl group was accomplished by treatment of **6** with Bu₄NOH in aq 1,4-dioxane, which gave the 4-*O*-methyl-galactopyranoside acceptor **7** in 82% yield (Scheme 1).

For the synthesis of the α -L-Fuc*p*-(1 \rightarrow 2)- β -D-Gal*p*-(1 \rightarrow OAllyl) disaccharide¹¹ derivatives, *S*-ethyl β -L-fucopyranosides were used as glycosyl donors. They were synthesized by *O*-acetylation (of known precursors¹²) to give the 3,4-di-*O*-acetyl derivatives **8** and **9**, respectively. Coupling of the glycosyl donors with the galactopyranoside acceptor derivatives was carried out under iodonium ion activation of the thioglycoside using *N*-iodosuccinimide and trifluoromethanesulphonic acid at -20° C in dichloromethane-diethyl ether.¹³ Coupling of donor **9** with acceptor **3** gave the α -(1 \rightarrow 2)- linked disaccharide derivative **10** in 58% yield together with the β -(1 \rightarrow 2)-linked isomer (18%). The ¹H NMR spectrum of **10** showed a doublet for H-1' at 5.53 ppm with a coupling constant of 3.7 Hz. Similar reactions with the 4-*O*-methylated acceptor **7** and the thiofucopyranoside donors **8** and **9** proceeded with better anomeric selectivity to furnish disaccharide **13** in 83% yield (and 6% of the β -isomer) and the dimethylated disaccharide **16** in 88% yield



ORDER		REPRINTS
-------	--	----------



Scheme 1.

(and 11% of the β -isomer, respectively). Acid hydrolysis of the *p*-methoxybenzyl or *p*-methoxybenzylidene group of derivatives **10** and **13** with 90% aq TFA followed by *O*-acetylation afforded the penta-*O*-acetyl disaccharides **11** and **14** in 84% and 65% yield, respectively. The *p*-methoxybenzyl ether groups of compound **16** were cleaved by the action of ceric ammonium nitrate. Subsequent *O*-acetylation gave the dimethylated disaccharide **17** in 76% overall yield. Zemplén de-*O*acetylation of the acetylated disaccharides and final purification furnished the disaccharides 2-*O*-Me- α -L-Fuc*p*-(1 \rightarrow 2)- β -D-Gal*p*-(1 \rightarrow *O*Allyl) **12**, α -L-Fuc*p*-(1 \rightarrow 2)-4-*O*-Me- β -D-Gal*p*-(1 \rightarrow *O*Allyl) **15** and 2-*O*-Me- α -L-Fuc*p*-(1 \rightarrow 2)-4-*O*-Me- β -D-Gal*p*-(1 \rightarrow *O*Allyl) **18** in 92%, 96% and 97% yield, respectively (Scheme 2).

Structural assignments were confirmed by the ¹³C NMR data (based on HMQC and HMBC spectra, Table 1) and compare favorably with data of related *O*-methylated oligosaccharides.¹⁴

The synthesis of the trisaccharides and immunochemical data derived from neoglycoconjugates will be published elsewhere.

EXPERIMENTAL

General methods. Melting points were determined with a Kofler hot stage and are uncorrected. Optical rotations were measured with a Perkin-Elmer 243 B polarimeter. ¹H NMR spectra were recorded with a Bruker DPX 300 instrument and tetramethylsilane or DSS as internal standards; coupling constants are first order. Homo- and heteronuclear 2D NMR spectroscopy was performed with Bruker standard software. Thin-layer chromatography was performed on Merck precoated plates (5 x 10 cm, layer thickness 0.25 mm, Silica Gel 60F₂₅₄); spots were detected by spraying with anisaldehyde-H₂SO₄ reagent. Column chromatography was per-



Downloaded by [Princeton University] at 20:00 08 October 2013

ORDER		REPRINTS
-------	--	----------





Scheme 2.

Unit	Carbon	12	15	18
α-L-Fucp	C-1	96.85	100.69	97.29
-	C-2	77.77	69.37	78.16
	C-3	68.98	70.58	69.37
	C-4	72.17	72.91	72.57
	C-5	66.89	67.84	67.29
	C-6	15.75	16.42	16.17
β-D-Gal <i>p</i>	C-1	100.99	101.54	101.30
	C-2	76.24	78.36	76.89
	C-3	74.18	75.02	74.89
	C-4	69.47	80.32	80.33
	C-5	75.31	76.16	75.83
	C-6	61.34	61.51	61.29
<i>O</i> All	C-1	133.72	134.41	134.15
	C-2	119.55	120.13	119.94
	C-3	71.40	71.97	71.77
<i>O</i> Me		57.84	62.45	62.34 (<i>O</i> -4)
				58.20 (O-2')

Table 1. ¹³C NMR Chemical Shifts^a (ppm) for Disaccharides **12**, **15** and **18**.

^a Spectra were recorded in D₂O at 295 K.







formed on Merck Lichroprep columns (size A, 24×1 ; B, 31×2.5 and C, 44×3.7 cm; silica gel 40–63 μ m) under pressure (0.2 MPa). Elemental analyses were performed by Dr. J. Theiner, Mikroanalytisches Laboratorium am Institut für Physikalische Chemie, Universität Wien.

Allyl 4,6-*O*-*p*-Methoxybenzylidene-β-D-galactopyranoside (2). A mixture of **1** (800 mg, 3.63 mmol), anisaldehyde dimethyl acetal (800 μL, 4.40 mmol) and *p*-toluenesulphonic acid monohydrate (100 mg) in dry acetonitrile (20 mL) was stirred for 4 h at rt. Neutralization with triethylamine (0.5 mL) and evaporation of the solvent gave a residue which was purified on silica gel (*C*, 50:1 CHCl₃/EtOH) to furnish **2** as colorless crystals. Yield: 1.0 g (81%); mp 179°C (hexane/EtOAc). $[\alpha]_D^{20} + 44^\circ$ (*c* 0.5, CHCl₃). ¹H NMR (CDCl₃) δ 7.45 - 6.80 (m, 4H, arom H), 5.97 (m, 1H, -CH=), 5.51 (s, 1H, MeOPhCH), 5.33 (dq, 1H, =CH_{2trans}), 5.23 (dq, 1H, =CH_{2cis}), 4.45 (ddt, 1H, OCH₂), 4.35 (d, 1H, *J*_{1,2} = 7.6 Hz, H-1), 4.33 (dd, 1 H, *J*_{5,6a} = 1.4, *J*_{6a,6b} = 12.5 Hz, H-6a), 4.20 (d, 1H, *J*_{3,4} = 3.9 Hz, H-4), 4.14 (ddt, 1H, OCH₂), 4.07 (dd, 1H, *J*_{5,6b} = 2.0 Hz, H-6b), 3.81 (s, 3H, OMe), 3.77 (ddd, 1H, *J*_{2,3} = 9.4, *J*_{2,OH} = 1.8 Hz, H-2), 3.68 (ddd, 1H, *J*_{3,OH} = 9.3 Hz, H-3), 3.47 (m, 1H, H-5) and 2.45–2.40 (m, 2H, OH).

Anal. Calcd for $C_{17}H_{22}O_7$ (338.36): C, 60.35; H, 6.55. Found: C, 59.83; H, 6.41.

Allyl 3-*O*-*p*-Methoxybenzyl-4,6-*O*-*p*-methoxybenzylidene-β-D-galactopyranoside (3). A mixture of **2** (1.1 g, 2.4 mmol) and dibutyltin oxide (800 mg, 3.21 mmol) in toluene (100 mL) was refluxed for 4 h with azeotropic removal of water. The solution was concentrated and the residue was dissolved in CH₃CN (20 mL). Tetrabutylammonium iodide (1.2 g, 3.24 mmol) and *p*-methoxybenzyl chloride (1.2 mL, 8.85 mmol) were added, and the mixture was refluxed overnight. Evaporation of the solvents gave a residue which was purified on silica gel (*C*, 1:1 hexane/EtOAc) to give **3** as colorless crystals, mp 182°C (hexane/EtOAc). Yield : 1.15 g (77%); $[\alpha]_{D}^{20}$ +43° (*c* 0.8, CHCl₃). ¹H NMR (CDCl₃) δ 7.50 - 6.80 (m, 8H, arom H), 5.98 (m, 1H, -CH=), 5.43 (s, 1H, MeOPhCH), 5.34 (dq, 1H, =CH_{2trans}), 5.23 (dq, 1H, =CH_{2cis}), 4.73 and 4.67 (AB, 2 H, *J*_{A,B} = 11.9 Hz, OCH₂Ph), 4.44 (ddt, 1H, OCH₂), 4.37 (d, 1H, *J*_{1,2} = 7.8 Hz, H-1), 4.31 (dd, 1H, *J*_{5,6a} = 1.4, *J*_{6a,6b} = 12.3 Hz, H-6a), 4.15 (ddt, 1H, OCH₂), 4.11 (d, 1H, *J*_{3,4} = 3.6 Hz, H-4), 4.07-3.97 (m, 2H, H-2, H-6b), 3.81 (s, 6H, 2 OMe), 3.48 (dd, 1H, *J*_{2,3} = 9.7 Hz, H-3), 3.35 (m, 1H, H-5) and 2.47 (d, 1H, *J*_{2,OH} = 1.9 Hz, OH).

Anal. Calcd for $C_{25}H_{30}O_8$ (458.51): C, 65.49; H, 6.59. Found: C, 64.84; H, 6.54.

Allyl 2-O-Acetyl-3-O-p-methoxybenzyl-4,6-O-p-methoxybenzylidene- β -D-galactopyranoside (4). A solution of 3 (800 mg, 1.74 mmol) and a catalytic amount of 4-*N*,*N*-dimethylaminopyridine in dry pyridine (10 mL) was stirred with acetic anhydride (1 mL) overnight at rt. MeOH (2 mL) was added, and the solution was coevaporated three times with addition of toluene and concentrated. Purification of the residue on silica gel (*C*, 2:1 hexane/EtOAc) furnished 4 as colorless

Marcel Dekker, Inc.

270 Madison Avenue, New York, New York 10016

ORDER		REPRINTS
-------	--	----------

crystals, mp 141°C (hexane/EtOAc). Yield: 800 mg (92%); $[\alpha]_D^{20} + 46^\circ$ (*c* 0.8, CHCl₃). ¹H NMR (CDCl₃) δ 7.50–6.80 (m, 8H, arom H), 5.85 (m, 1H, -CH=), 5.43 (s, 1H, MeOPhCH), 5.36 (dd, 1H, $J_{1,2} = 8.0, J_{2,3} = 10.1$ Hz, H-2), 5.26 (dq, 1H, =CH_{2trans}), 5.15 (dq, 1H, =CH_{2cis}), 4.62 and 4.55 (AB, 2H, $J_{A,B} = 12.3$ Hz, OCH₂Ph), 4.45 (d, 1H, H-1), 4.35 (ddt, 1H, OCH₂), 4.29 (dd, 1H, $J_{5,6a} = 1.6, J_{6a,6b} = 12.4$ Hz, H-6a), 4.12 (d, 1H, $J_{3,4} = 3.5$ Hz, H-4), 4.10 (ddt, 1H, OCH₂), 4.01 (dd, 1H, $J_{5,6b} = 1.8$ Hz, H-6b), 3.80 (s, 6H, 2 OMe), 3.56 (dd, 1H, H-3), 3.32 (m, 1H, H-5), and 2.06 (s, 3H, Ac).

Anal. Calcd for C₂₇H₃₂O₉ (500.54): C, 64.79; H, 6.44. Found: C, 64.39; H, 6.28.

Allyl 2-*O*-Acetyl-3,6-di-*O*-*p*-methoxybenzyl-β-D-galactopyranoside (5). A suspension of **4** (200 mg, 0.4 mmol), 4 Å molecular sieves (0.4 g) in DMF (5 mL) and NaCNBH₃ (450 mg, 7.16 mmol) was stirred under Ar at rt. After 15 min, trifluoroacetic acid (400 µL, 5.19 mmol) in DMF (2 mL) was added dropwise at 0°C. The suspension was stirred overnight at room temperature. Triethylamine (0.5 mL) was added, and the mixture was filtered over a pad of Celite. The filtrate was concentrated and the residue was purified on a column of silica gel (*C*, 3:2 hexane/EtOAc) to give **5** as a syrup. Yield: 140 mg (70%); $[\alpha]_D^{20} + 8^\circ$ (*c* 0.8, CHCl₃).¹H NMR (CDCl₃) δ 7.35 - 6.85 (m, 8H, arom H), 5.85 (m, 1H, -CH=), 5.26 (dq, 1H, =CH_{2trans}), 5.20 (dd, 1H, $J_{1,2} = 8.1, J_{2,3} = 9.8$ Hz, H-2), 5.16 (dq, 1H, =CH_{2cis}), 4.63 and 4.48 (AB, 2H, $J_{A,B} = 11.9$ Hz, OCH₂Ph), 4.53 (s, 2H, OCH₂Ph), 4.38 (d, 1H, H-1), 4.33 (ddt, 1H, OCH₂), 4.15–4.00 (m, 2H, H-4, OCH₂), 3.82 (s, 6H, 2 OMe), 3.81 (dd, 1H, $J_{5,6a} = 6.2, J_{6a,6b} = 9.9$ Hz, H-6a), 3.72 (dd, 1H, $J_{5,6b} = 5.8$ Hz, H-6b), 3.70 (dd, 1H, H-5), 3.47 (dd, 1H, $J_{3,4} = 3.4$ Hz, H-3), 2.56 (bs, 1H, OH), and 2.05 (s, 3H, Ac).

Anal. Calcd for $C_{27}H_{34}O_9$ (502.57): C, 64.53; H, 6.82. Found: C, 64.10; H, 6.83. Further elution afforded the 4-*O*-isomer as a syrup. Yield: 40 mg (20%).

Allyl 2-*O*-Acetyl-3,6-di-*O*-*p*-methoxybenzyl-4-*O*-methyl-β-D-galactopyranoside (6). A suspension of 5 (95 mg, 0.19 mmol) in dry DMF (3 mL) and NaH (12 mg, 80% in oil, 0.4 mmol) was stirred at rt. After stirring for 15 min, MeI (60 μL, 0.96 mmol) was added at -20° C and stirring was continued for 2 h. The mixture was diluted with CH₂Cl₂, filtered over a pad of Celite, washed with 10% aq Na₂S₂O₃, satd aq NaHCO₃ and dried (Na₂SO₄). Concentration of the solution and purification of the residue on a column of silica gel (*C*, 3:2 hexane/EtOAc) afforded **6** as a syrup. Yield: 85 mg (87%); $[\alpha]_D^{20} + 8^{\circ}$ (*c* 1.2, CHCl₃).¹H NMR (CDCl₃) δ 7.27–6.75 (m, 8H, arom H), 5.81 (m, 1H, -CH=), 5.25 (dd, 1H, *J*_{1,2} = 8.0, *J*_{2,3} = 9.8, H-2), 5.22 (dq, 1H, =CH_{2trans}), 5.12 (dq, 1H, =CH_{2cis}), 4.64, 4.51 and 4.46 (AB, 4H, *J*_{A,B} 11.5 Hz, 2 OCH₂Ph), 4.35 (d, 1H, H-1), 4.28 (ddt, 1H, OCH₂), 4.03 (ddt, 1H, OCH₂), 3.81, 3.80 (2 s, 6H, 2 MeOPh), 3.71 (dd, 1H, *J*_{5,6a} = 7.5, *J*_{6a,6b} = 9.0 Hz, H-6a), 3.66 (d, 1H, *J*_{3,4} = 3.0 Hz, H-4), 3.60 (dd, 1H, *J*_{5,6b} = 5.4 Hz, H-6b), 3.54 (s, 3H, OMe), 3.51 (dd, 1H, H-5), 3.43 (dd, 1H, H-3), and 2.02 (s, 3H, Ac).



Copyright © Marcel Dekker, Inc. All rights reserved

ORDER		REPRINTS
-------	--	----------

Downloaded by [Princeton University] at 20:00 08 October 2013

Anal. Calcd for C₂₈H₃₆O₉ (516.59): C, 65.10; H, 7.02. Found: C, 64.90; H, 6.92.

Allyl 3,6-Di-*O*-*p*-methoxybenzyl-4-*O*-methyl-β-D-galactopyranoside (7). Compound 6 (65 mg, 0.13 mmol) was dissolved in 90% aq dioxane (5 mL), and 40% aq tetra-*n*-butylammonium hydroxide (100 µL, 0.22 mmol) was added. After stirring for 4 h at rt, the solution was neutralized by addition of Dowex 50 (H⁺) resin, the resin was filtered off, and the filtrate was concentrated. The residue was purified on a column of silica gel (*C*, 3:2 hexane/EtOAc) to give 7 as a syrup. Yield: 48 mg (82%); $[\alpha]_D^{20} - 5^\circ$ (*c* 1.2, CHCl₃).¹H NMR (CDCl₃) δ 7.35–6.85 (m, 8H, arom H), 5.92 (m, 1H, =CH-), 5.28 (dq, 1H, =CH_{2trans}), 5.17 (dq, 1H, =CH_{2cis}), 4.71, 4.60, 4.51 and 4.46 (AB, 4H, *J*_{A,B} = 11.5 Hz, OCH₂Ph), 4.35 (ddt, 1H, OCH₂), 4.27 (d, 1H, *J*_{1,2} = 7.7 Hz, H-1), 4.08 (ddt, 1H, OCH₂), 4.00–3.79 (m, 7H, H-2, 2 MeOPh), 3.70 (dd, 1H, *J*_{5,6a} = 7.6, *J*_{6a,6b} = 8.9 Hz, H-6a), 3.64 (d, 1H, *J*_{3,4} = 3.7 Hz, H-4), 3.59 (dd, 1H, *J*_{5,6b} = 5.3 Hz, H-6b), 3.56 - 3.50 (m, 4H, H-5, OMe), 3.36 (dd, 1H, *J*_{2,3} = 9.9 Hz, H-3), and 2.31 (bs, 1H, OH).

Anal. Calcd for $C_{26}H_{34}O_8$ (474.55): C, 65.81; H, 7.22. Found: C, 65.76; H, 7.27.

S-Ethyl 3,4-Di-*O*-acetyl-2-*O*-*p*-methoxybenzyl-1-thio-β-L-fucopyranoside (8). A solution of *S*-ethyl 3,4-*O*-isopropylidene-2-*O*-*p*-methoxybenzyl-1-thio-β-L-fucopyrano-side (150 mg, 0.41 mmol) in CH₂Cl₂ (10 mL) was treated with 90% aq trifluoroacetic acid (150 µL) at -35° C for 2 h. Triethylamine (0.5 mL) was added, and the solvent was evaporated. The residue was dissolved in pyridine (3 mL) and stirred with a catalytic amount of 4-*N*,*N*-dimethylaminopyridine and acetic anhydride (1 mL) for 48 h at rt. Methanol (2 mL) was added, and the solution was concentrated. Purification of the residue on silica gel (*C*, 3:1 hexane/EtOAc) afforded **8** as a syrup; Yield: 65 mg (39%).[α]_D²⁰ -9° (*c* 0.7, CHCl₃). ¹H NMR (CDCl₃) δ 7.30–6.80 (m, 4H, arom. H), 5.25 (dd, 1H, *J*_{3,4} = 3.4 Hz, H-4), 4.99 (dd, 1H, *J*_{2,3} = 9.7 Hz, H-3), 4.78 and 4.54 (d, 2H, *J*_{A,B} = 10.5 Hz, OCH₂Ph), 4.54 (d, 1H, *J*_{1,2} = 9.7 Hz, H-1), 3.79 (s, 1H, OMe), 3.76 (dd, 1H, *J*_{5,6} = 6.4 Hz, H-5), 3.62 (dd, 1H, H-2), 2.77 (m, 2H, SCH₂), 2.15 and 1.97 (2 s, 6H, 2 Ac), 1.33 (t, 3H, CH₂*CH*₃), and 1.20 (d, 3H, H-6).

Anal. Calcd for $C_{20}H_{28}O_7S$ (412.51): C, 58.24; H, 6.84. Found: C, 57.95; H, 6.78.

S-Ethyl 3,4-Di-O-acetyl-2-O-methyl-1-thio- β -L-fucopyranoside (9). A solution of S-ethyl 3,4-O-isopropylidene-2-O-methyl-1-thio- β -D-fucopyranoside (500 mg, 1.91 mmol) in CH₂Cl₂ (40 mL) was treated with 90% aq trifluoroacetic acid (1 mL) at rt for 2 h. Triethylamine (0.5 mL) was added, and the solvent was evaporated. The residue was dissolved in pyridine (20 mL) and stirred with a catalytic amount of 4-*N*,*N*-dimethylaminopyridine and acetic anhydride (3 mL) for 48 h at rt. Methanol (6 mL) was added, and the solution was concentrated. Purification of the residue on silica gel (*C*, 3:1 hexane/EtOAc) afforded **9** as a syrup.Yield:



725

ORDER		REPRINTS
-------	--	----------

520 mg (89%); $[\alpha]_D^{20}$ +17° (*c* 0.6, CHCl₃).¹H NMR (CDCl₃) δ 5.24 (dd, 1H, $J_{5,4}$ = 1.0, $J_{3,4}$ = 3.4 Hz, H-4), 4.93 (dd, 1H, $J_{2,3}$ = 9.7 Hz, H-3), 4.43 (d, 1H, $J_{1,2}$ = 9.7 Hz, H-1), 3.76 (dd, 1H, $J_{5,6}$ = 6.5 Hz, H-5), 3.52 (s, 3H, OMe), 3.35 (dd, 1H, H-2), 2.77 (m, 2H, SCH₂), 2.16, 2.04 (2 s, 6H, 2 Ac), 1.32 (t, 3H, CH₂CH₃), and 1.19 (d, 3H, $J_{5,6}$ = 6.5 Hz, H-6).

Anal. Calcd for $C_{13}H_{22}O_6S$ (306.38): C, 50.96; H, 7.24. Found: C, 51.26; H, 7.41.

(3,4-Di-O-acetyl-2-O-methyl-α-L-fucopyranosyl)-(1(2)-3-O-p-Allvl methoxy-benzyl-4,6-*O*-*p*-methoxybenzylidene-β-D-galactopyranoside (10). To a suspension of 3 (95 mg, 0.21 mmol), 9 (83 mg, 0.27 mmol), and powderedmolecular sieves 4 Å (0.2 g) in CH₂Cl₂/Et₂O (1:1, v/v, 2 mL) was added a solution of N-iodosuccinimide (16 mg) and trifluoromethanesulphonic acid (4 μ L) in CH_2Cl_2/Et_2O (1:1, v/v, 2 mL) at $-20^{\circ}C$ under Ar. The mixture was stirred at $0^{\circ}C$ for 1 h, diluted with CH₂Cl₂ (50 mL), and filtered over a pad of Celite. The filtrate was washed with 10% aq Na₂S₂O₃, aq satd NaHCO₃, dried (Na₂SO₄) and concentrated. Purification of the residue on silica gel (C, 3:1:1 toluene/EtOAc/MeOH, v/v/v) gave **10** as a syrup. Yield: 77 mg (53%); $[\alpha]_{\rm D}^{20} - 47^{\circ}$ (c 0.6, CHCl₃). ¹H NMR (CDCl₃) & 7.45-6.75 (m, 8H, arom H), 5.93 (m, 1H, -CH=), 5.53 (d, 1H, $J_{1',2'} = 3.7$ Hz, H-1'), 5.36 (s, 1H, PhCH), 5.34 - 5.15 (m, 4H, H-3', H-4', $=CH_{2trans}$, $=CH_{2cis}$), 4.66 and 4.56 (AB, 2H, $J_{A,B} = 11.4 \text{ OCH}_2\text{Ph}$), 4.62 (dd, 1H, $J_{5',6'} = 6.5$ Hz, H-5'), 4.48 (d, 1H, $J_{1,2} = 7.8$, H-1), 4.40 (ddt, 1H, OCH₂), 4.28 (dd, 1H, OCH₂), 4 1H, $J_{6a,6b} = 12.2$ Hz, H-6a), 4.14–4.02 (m, 3H, H-2, H-4, OCH₂), 3.98 (dd, 1H, $J_{5,6a} = 1.6$ Hz, H-6b), 3.81 and 3.79 (2 s, 6H, 2 MeOPh), 3.72 (dd, 1H, $J_{2,3} = 9.5$, $J_{3,4} = 3.7$ Hz, H-3), 3.56 (dd, 1H, $J_{2',3'} = 10.5$ Hz, H-2'), 3.36 (s, 3H, OMe), 3.31 (m, 1H, H-5), 2.14 and 2.01 (2 s, 6H, 2 Ac), and 1.04 (d, 3H, H-6').

Anal. Calcd for $C_{36}H_{46}O_{14}$ (702.76): C, 61.53; H, 6.60. Found: C, 61.26; H, 6.51. Further elution furnished the β -isomer as a syrup. Yield: 25 mg (18%); ¹H NMR (CDCl₃) for anomeric protons δ 4.92 (d, 1H, $J_{1',2'}$ = 7.8 Hz, H-1'), and 4.45 (d, 1H, $J_{1,2}$ = 7.8 Hz, H-1).

Allyl (3,4-Di-*O*-acetyl-2-*O*-*p*-methoxybenzyl-β-L-fucopyranosyl)-(1→2)-3,6-di-*O*-*p*-methoxybenzyl-4-*O*-methyl-β-D-galactopyranoside (13). Compound 7 (45 mg, 0.10 mmol) was reacted with 8 (50 mg, 0.12 mmol) in the same way as described for 10. Purification of the residue on silica gel (*C*, 3:2 hexane/EtOAc) afforded 13 as syrup. Yield: 65 mg (83%); $[\alpha]_D^{20} - 60^\circ$ (*c* 0.7, CHCl₃). ¹H NMR (CDCl₃) δ 7.30–6.50 (m, 12H, arom H), 5.90 (m, 1H, -CH=), 5.57 (d, 1H, $J_{1',2'} = 3.8$ Hz, H-1'), 5.35 - 5.10 (m, 4H, H-3', H-4', =CH_{2trans}, =CH_{2cis}), 4.71 and 4.28 (AB, 2H, $J_{A,B} = 11.9$ Hz, OCH₂Ph), 4.65 (dd, 1H, $J_{5',6'}$ = 6.5 Hz, H-5'), 4.52–4.40 (m, 5H, H-1, 2 OCH₂Ph), 4.35 (ddt, 1H, OCH₂), 4.10–3.95 (m, 2H, H-2, OCH₂), 3.80, 3.79 and 3.75 (3 s, 9H, 3 MeOPh), 3.75 (dd, 1H, $J_{2',3'} = 10.7$ Hz, H-2'), 3.72–3.49 (m, 5H, H-3, H-4, H-5, H-6a, H-6b), 3.48 (s, 3H, OMe), 2.06 and 1.95 (2 s, 6H, 2 Ac), and 1.02 (d, 3H, H-6').

Anal. Calcd for $C_{44}H_{56}O_{15}$ (824.93): C, 64.07; H, 6.84. Found: C, 63.56; H, 6.77. Further elution furnished the β -isomer as a syrup. Yield: 6 mg (7%). ¹H NMR



ORDER		REPRINTS
-------	--	----------

(CDCl₃) for anomeric protons δ 4.96 (d, 1H, $J_{1',2'}$ = 7.8 Hz, H-1'), and 4.37 (d, 1H, $J_{1,2}$ = 7.7 Hz, H-1).

Allyl (3,4-Di-*O*-acetyl-2-*O*-methyl- α -L-fucopyranosyl)-(1 \rightarrow 2)-3,6-di-*Op*-methoxybenzyl-4-*O*-methyl-β-D-galactopyranoside (16). To a mixture of 7 (45 mg, 0.09 mmol), 9 (40 mg, 0.13 mmol) and powdered molecular sieves 4 Å (0.2 g) in CH₂Cl₂/Et₂O (1:1, v/v, 2 mL) was added a solution of N-iodosuccinimide (16 mg) and trifluoromethanesulphonic acid (4 μ L) in CH₂Cl₂/Et₂O (1:1, v/v, 2 mL) at -20° C under Ar. The suspension was stirred at 0° C for 1 h, diluted with CH₂Cl₂ (50 mL) and filtered over Celite. The filtrate was washed with 10% aq Na₂S₂O₃, aq NaHCO₃, dried over Na₂SO₄ and concentrated. Purification of the residue on silica gel (B, 3:1 hexane/EtOAc) gave contaminated product 16, which could not be further purified at this stage. Yield: 60 mg (88%). ¹H NMR (CDCl₃) δ 7.30–6.80 (m, 8H, arom H), 5.88 (m, 1H, -CH=), 5.55 (d, 1H, $J_{1',2'}$ = 3.7 Hz, H-1'), 5.35–5.10 (m, 4H, H-3', H-4', =CH_{2trans}, =CH_{2cis}), 4.71 and 4.53 (AB, 2H, $J_{AB} = 11.1$ Hz, OCH₂Ph), 4.62 (dd, 1H, $J_{5',6'} = 6.5$ Hz, H-5'), 4.48 and 4.47 (2 s, 2H, OCH₂Ph), 4.43 (d, 1H, J_{1,2} = 7.7 Hz, H-1), 4.35 (ddt, 1H, OCH₂), 4.10–3.95 (m, 2H, H-2, OCH₂), 3.81 and 3.79 (2 s, 6H, 2 MeOPh), 3.70–3.50 (m, 6H, H-3, H-4, H-5, H-6a, H-6b, H-2'), 3.49 and 3.30 (2 s, 3H, 2 OMe), 2.13 and 1.99 (2s, 6H, 2 Ac), and 1.02 (d, 3H, H-6').

Further elution furnished the β -isomer as a syrup. Yield: 8 mg (11%). ¹H NMR (CDCl₃) for anomeric protons δ 4.87 (d, 1H, $J_{1',2'}$ = 7.7 Hz, H-1'), and 4.37 (d, 1H, $J_{1,2}$ = 7.7 Hz, H-1)

Allyl (3,4-Di-*O*-acetyl-2-*O*-methyl-α-L-fucopyranosyl)-(1→2)-3,4,6-tri-*O*-ace-tyl-β-D-galactopyranoside (11). A solution of 10 (28 mg, 0.04 mmol) in CH₂Cl₂ (3 mL) was treated with aq 90% trifluoroacetic acid (100 µL) at rt for 1 h. The mixture was neutralized with triethylamine (0.5 mL), and the solvent was evaporated. The residue was dissolved in pyridine (2 mL) and stirred with a catalytic amount of 4-*N*,*N*-dimethylaminopyridine and acetic anhydride (200 µL) overnight at rt. MeOH (1 mL) was added, and the solution was concentrated. Purification of the residue on silica gel (*B*, 1:2 hexane/EtOAc) afforded 11 as a syrup. Yield: 15 mg (65%); $[\alpha]_D^{20} - 46^\circ$ (*c* 1.0, CHCl₃). ¹H NMR (CDCl₃) δ 5.93 (m, 1H, -CH=), 5.37 (d, 1H, J_{3,4} = 3.4 Hz, H-4), 5.32 (dq, 1H, =CH_{2trans}), 5.28–5.15 (m, 4H, H-1', H-3', H-4', =CH_{2cis}), 5.10 (dd, 1H, J_{2,3} = 10.1 Hz, H-3), 4.55 (d, 1H, J_{1,2} = 7.8 Hz, H-1), 4.51 (dd, 1H, J_{5',6'} = 6.5 Hz, H-5'), 4.40 (ddt, 1H, OCH₂), 4.25–4.05 (m, 3H, H-6a, H-6b, OCH₂), 3.98 (dd, 1H, H-2), 3.87 (dd, 1H, J_{5,6a} = J_{5,6b} = 6.7 Hz, H-5), 3.61 (dd, 1H, J_{1',2'} = 3.7, J_{2',3'} = 10.1 Hz, H-2'), 3.39 (1 s, 3H, OMe), 2.15, 2.12, 2.05, 2.00 and 1.99 (5s, 15H, 5 Ac), and 1.08 (d, 3H, H-6').

Anal. Calcd for $C_{26}H_{38}O_{15}$ (590.58): C, 52.88; H, 6.49. Found: C, 53.20; H, 6.44.

Allyl (2,3,4-Tri-*O*-acetyl-α-L-fucopyranosyl)-(1 \rightarrow 2)-3,6-di-*O*-acetyl-4-*O*-methyl-β-D-galactopyranoside (14). A solution of 13 (55 mg, 0.07 mmol) in CH₂Cl₂ (8 mL) was treated with aq 90% trifluoroacetic acid (150 µL) at rt for 1 h.

Copyright @ Marcel Dekker, Inc. All rights reserved.



ORDER		REPRINTS
-------	--	----------

The mixture was neutralized with triethylamine (0.5 mL), and the solvent was evaporated. The residue was dissolved in pyridine (3 mL) and stirred with a catalytic amount of 4-*N*,*N*-dimethylaminopyridine and acetic anhydride (400 µL) overnight at rt. MeOH (1 mL) was added, and the solution was concentrated. Purification of the residue on silica gel (*B*, 1:1 hexane/EtOAc) afforded **14** as a syrup. Yield: 33 mg (84%); $[\alpha]_D^{20} - 117^\circ$ (*c* 0.6, CHCl₃). ¹H NMR (CDCl₃) δ 5.90 (m, 1H, =CH-), 5.40 (d, 1H, $J_{1',2'} = 3.9$ Hz, H-1'), 5.40 (dd, 1H, $J_{2',3'} = 10.9$, $J_{3',4'} = 3.4$ Hz, H-3'), 5.29 (dq, 1H, =CH_{2trans}), 5.26–5.18 (m, 2H, H-4', =CH_{2cis}), 5.02 (dd, 1H, H-2'), 4.94 (dd, 1H, $J_{2,3} = 9.9$, $J_{3,4} = 3.0$ Hz, H-3), 4.57 (dd, 1H, $J_{5',6'} = 6.5$ Hz, H-5'), 4.45 (d, 1H, $J_{1,2} = 7.7$ Hz, H-1), 4.38 (ddt, 1H, OCH₂), 4.32 (dd, 1H, $J_{5,6a} = 6.4$, $J_{6a,6b} = 11.1$ Hz, H-6a), 4.18 (dd, 1H, $J_{5,6b} = 6.6$ Hz, H-6b), 4.08 (ddt, 1H, OCH₂), 4.06 (dd, 1H, H-2), 3.67 (dd, 1H, H-5), 3.57 (d, 1H, H-4), 3.46 (1 s, 3H, OMe), 2.14, 2.11, 2.08, 2.02 and 1.98 (5 s, 15H, 5 Ac), and 1.06 (d, 3H, H-6').

Anal. Calcd for $C_{26}H_{38}O_{15}$ (590.58): C, 52.88; H, 6.49. Found: C, 53.58; H, 6.43.

Allyl (3,4-Di-*O*-acetyl-2-*O*-methyl- α -L-fucopyranosyl)-(1 \rightarrow 2)-3,6-di-*O*acetyl-4-O-methyl-B-D-galactopyranoside (17). To a solution of 16 (54 mg, 0.08 mmol) in 9:1 CH₃CN/H₂O (5 mL) was added ceric ammonium nitrate (300 mg, 0.55 mmol) and 2 drops of pyridine, and the mixture was stirred for 2 h at rt. Additional ceric ammonium nitrate (100 mg) was added and stirring was continued for 1 h. The mixture was diluted with CH₃CN (10 mL), filtered over a pad of Celite, and the solvent was evaporated. The residue was dissolved in pyridine (3 mL) and stirred with a catalytic amount of 4-N,N-dimethylaminopyridine and acetic anhydride (0.5 mL) at rt for 12 h. MeOH (2 mL) was added, and the solution was concentrated. Purification of the residue on silica gel (B, 2:1 hexane/EtOAc) afforded **16** as a syrup. Yield: 32 mg (76%); $[\alpha]_D^{20} - 88^\circ$ (*c* 0.7, CHCl₃). ¹H NMR (CDCl₃) δ 5.89 (m, 1H, -CH=), 5.35 - 5.10 (m, 5H, H-1', 3', 4', =CH_{2trans}, =CH_{2cis}), 4.98 (dd, 1H, $J_{2,3}$ = 10.3, $J_{3,4}$ = 3.0 Hz, H-3), 4.56 (dd, 1H, $J_{5',6'}$ = 6.5 Hz, H-5'), 4.45 (d, 1H, $J_{1,2} = 7.7$ Hz, H-1), 4.40–4.25 (m, 2H, H-6a, OCH₂), 4.17 $(dd, 1H, J_{5.6b} = 6.5, J_{6a.6b} = 11.1 Hz, H-6b), 4.13-4.00 (m, 2H, H-2, OCH₂), 3.75$ - 3.55 (m, 3H, H-4, 5, 2'), 3.46 and 3.41 (2 s, 6H, 2 OMe), 2.14, 2.11, 2.07 and 1.99 (4 s, 12H, 4 Ac), and 1.04 (d, 3H, H-6').

Anal. Calcd for $C_{25}H_{38}O_{14}$ (562.57): C, 53.38; H, 6.81. Found: C, 53.61; H, 6.62.

Allyl 2-*O*-Methyl- α -L-fucopyranosyl-(1 \rightarrow 2)- β -D-galactopyranoside (12). A solution of 11 (19 mg, 0.032 mmol) in dry MeOH (3 mL) was stirred with 0.1 M methanolic NaOMe (200 μ L) overnight at rt. The pH of the solution was adjusted to 7.0 by addition of Dowex 50 (H⁺) resin, the resin was filtered off, and the filtrate was concentrated. Purification of the residue on silica gel (*A*, 1:2 MeOH/EtOAc) afforded 12 as a syrup. Yield: 12 mg (96%); [α]_D²⁰ –134° (*c* 0.6, MeOH). ¹H NMR (D₂O) δ 5.97 (m, 1H, -CH=), 5.44 (d, 1H, $J_{1',2'}$ = 3.9 Hz, H-1'), 5.35 (dq, 1H, =CH_{2trans}), 5.27 (dq, 1H, =CH_{2cis}), 4.52 (d, 1H, $J_{1,2}$ = 7.9 Hz, H-1), 4.38 (ddt, 1H, OCH₂), 4.31 (dd, 1H, $J_{5',6'}$ = 6.6 Hz, H-5'), 4.21 (ddt, 1H, OCH₂), 3.90–3.63 (m,



ORDER		REPRINTS
-------	--	----------

7H, H-3, H-4, 5, 6a, 6b, 3', 4'), 3.60 (dd, 1H, $J_{2,3} = 9.6$ Hz, H-2), 3.49 (s, 3H, OMe), 3.47 (dd, 1H, $J_{2',3'} = 10.5$ Hz, H-2'), and 1.17 (d, 3H, H-6').

Anal. Calcd for C₁₆H₂₈O₁₀ (380.39): C, 50.52; H, 7.42. Found: C, 49.69; H, 7.19.

Allyl α -L-Fucopyranosyl-(1 \rightarrow 2)-4-*O*-methyl- β -D-galactopyranoside (15). A solution of 14 (27 mg, 0.046 mmol) in dry MeOH (5 mL) was stirred with 0.1 M methanolic NaOMe (100 µL) for 48 h at rt. The pH of the solution was adjusted to 7.0 by addition of Dowex 50 (H^+) resin, the resin was filtered off, and the residue was concentrated. Purification of the residue on silica gel (A, 1:3 MeOH/EtOAc)afforded **15** as a syrup. Yield: 16 mg (92%); $[\alpha]_D^{20} - 129^\circ$ (*c* 0.9, MeOH). ¹H NMR (D₂O) δ 5.98 (m, 1H, -CH=), 5.35 (dq, 1H, =CH_{2trans}), 5.28 (dq, 1H, =CH_{2cis}), 5.17 (d, 1H, $J_{1',2'} = 3.7$ Hz, H-1'), 4.50 (d, 1H, $J_{1,2} = 7.8$ Hz, H-1), 4.37 (ddt, 1H, OCH₂), 4.31 (dd, 1H, *J*_{5',6'} = 6.6 Hz, H-5'), 4.21 (ddt, 1H, OCH₂), 3.95–3.73 (m, 6H, H-3, 6a, 6b, 2', 3', 4'), 3.68 (dd, 1H, $J_{5,6a} = 6.4 J_{5,6b} = 6.2$ Hz, H-5), 3.62 (d, 1H, $J_{3,4} = 3.4$ Hz, H-4), 3.60–3.45 (m, 4H, H-2, OMe), and 1.18 (d, 3H, H-6').

Anal. Calcd for C₁₆H₂₈O₁₀ (380.39): C, 50.52; H, 7.42. Found: C, 49.82; H, 7.31.

Allyl 2-*O*-Methyl- α -L-fucopyranosyl- $(1 \rightarrow 2)$ -4-*O*-methyl- β -D-galactopyrano-side (18). A solution of 17 (22 mg, 0.039 mmol) in dry MeOH (3 mL) was stirred with 0.1 M methanolic NaOMe (100 μ L) for 3 h at rt. The pH of the solution was adjusted to 7.0 by addition of Dowex 50 (H⁺) resin, the resin was filtered off, and the residue was concentrated. Purification of the residue on silica gel (A, 1:3 MeOH/EtOAc) afforded 18 as a syrup. Yield: 15 mg (97%); $[\alpha]_D^{20} - 138^\circ$ $(c \ 0.7, \text{ MeOH})$. ¹H NMR (D₂O) δ 5.96 (m, 1H, -CH=), 5.41 (d, 1H, $J_{1'2'} = 3.8$ Hz, H-1'), 5.33 (dq, 1H, =CH_{2trans}), 5.26 (dq, 1H, =CH_{2cis}), 4.49 (d, 1H, $J_{1,2}$ = 7.8 Hz, H-1), 4.40-4.25 (m, 2H, H-5', OCH₂), 4.19 (ddt, 1H, OCH₂), 4.00-3.70 (m, 5H, H-3, 6a, 6b, 3', 4'), 3.67 (dd, 1H, $J_{5,6a} = 5.8$, $J_{5,6b} = 6.8$ Hz, H-5), $3.60-3.40 \text{ (m, 9H, H-2, 4, 2', 2 OMe)}, 1.06 \text{ (d, 3H, } J_{5',6'} = 6.5 \text{ Hz, H-6')}.$

Anal. Calcd for C₁₇H₃₀O₁₀ (394.42): C, 51.77; H, 7.67. Found: C, 51.02; H, 7.43

ACKNOWLEDGMENTS

Technical assistance by Maria Hobel is gratefully acknowledged. The authors are grateful for a scholarship by ÖAD (Austrian Academic Exchange Office) and the Cultural Office of the Republic of Egypt.

REFERENCES

- Dedicated to Prof. Joachim Thiem on the occasion of his 60th birthday. 1.
- a) Maizels, R. M.; Bundy, D. A. P.; Selkirk, M. E.; Smith, D. F.; Anderson, R. M. Im-2. munological modulation and evasion by helminth parasites in human populations.

ORDER		REPRINTS
-------	--	----------

Nature **1993**, *365*, 797–805. b) Maizels, R. M.; Gems, D. H.; Page, A. P. Synthesis and secretion of TES antigens from *Toxocara canis* infective larvae. In *Toxocara and Toxocariasis, Clinical, Epidemiological and Molecular Perspectives,* Lewis, J. W.; Maizels, R. M. Ed.; British Society for Parasitology and Institute of Biology, **1993**; 141–150.

- Gems, D.; Maizels, R. M. An abundantly expressed mucin-like protein from *Toxo-cara canis* infective larvae: the precursor of the larval surface coat glycoprotein. Proc. Natl. Acad. Sci. USA 1996, 93, 1665–1670.
- Khoo, K-H.; Maizels, R. M.; Page, A. P.; Taylor, G. W.; Rendell, N. B.; Dell, A. Characterization of nematode glycoproteins: the major *O*-glycans of *Toxocara* excretory-secretory antigens are *O*-methylated trisaccharides. Glycobiology **1991**, *1*, 163–171.
- a) Page, A. P.; Hamilton, A. J.; Maizels, R. M. Toxocara canis: Monoclonal antibodies to carbohydrate epitopes of secreted (TES) antigens localize to different secretionrelated structures in infective larvae. Exp. Parasitol. **1992**, *75*, 56–71. b) Loukas, A.; Hintz, M.; Linder, D.; Mullin, N. P.; Parkinson, J.; Tetteh, K. K. A.; Maizels, R. M. A family of secreted mucins from the parasitic nematode *Toxocara canis* bears diverse mucin domains but shares similar flanking six-cysteine repeat motifs. J. Biol. Chem. **2000**, *275*, 39600–39607.
- Lee, R. T.; Lee, Y. C. Synthesis of 3-(2-aminoethylthio)propyl glycosides. Carbohydr. Res. 1974, 37, 193–201.
- Jacquinet, J. C.; Sinaÿ, P. Synthese des substances de groupe sanguin-IX. Tetrahedron 1979, 35, 365–371.
- Du, M-H.; Spohr, U.; Lemieux, R. U. The recognition of three different epitopes for the H-type 2 human blood group determinant by lectins of *Ulex europaeus, Galactia tenuiflora* and *Psophocarpus tetragonolobus* (Winged bean). Glycoconjugate J. 1994, 11, 443–461.
- David, S.; Thieffry, A.; Veyrières; A. A mild procedure for the regiospecific benzylation and allylation of polyhydroxy-compounds via their stannylene derivatives in non-polar solvents. J. Chem. Soc., Perkin Trans. 1 1981, 1796–1981.
- Johansson, R.; Samuelsson, B. Regioselective ring-opening of 4-methoxybenzylidene acetals of hexopyranosides. Access to a novel protecting-group strategy. Part 1. J. Chem. Soc., Perkin Trans. 1 1984, 2371–2374.
- For examples see a) Åberg, P. M.; Blomberg, L.; Lönn, H.; Norberg, T. Large scale synthesis of two trisaccharide spacer glycosides corresponding to the blood group A and B determinants using thioglycosides and dimethyl(thiomethyl)sulfonium tetrafluoroborate (DMTSB) as promoter. J. Carbohydr. Chem. **1994**, *13*, 141–161. b) Schmid, U.; Waldmann, H. Synthesis of fucosyl saccharides under neutral conditions in solutions of lithium perchlorate in dichloromethane. Chem. Eur. J. **1998**, *4*, 494–501. c) Kolár, C.; Paulsen, H. Synthese der Oligosaccharid-Determinanten der Blutgruppensubstanzen der Type 2 des ABH-Systems. Chem. Ber. **1981**, *114*, 306–321.
- a) Steindl, C.; Kosma, P.; März, L.; Neszmélyi, A. Short synthesis of allyl 2-acetamido-2-deoxy-3,6-di-*O*-(α-L-fucopyranosyl)-β-D-glucopyranoside. Carbohydr. Res. **1993**, *246*, 353–360. b) Jain, R. K.; Matta, K. L. Methyl 3,4-*O*-isopropylidene-2-*O*-(4-methoxybenzyl)-1-thio-β-L-fucopyranoside–a novel, efficient glycosylating reagent for the synthesis of linear and other α-L-fucosyl oligosaccharides. Tetrahedron Lett. **1990**, *31*, 4325–4328. c) Zegelaar-Jaarsveld, K.; van der Marel, G. A.; van



|--|

Boom, J. H. Iodonium ion assisted synthesis of a common inner core trisaccharide fragment corresponding to the cell-wall phenolic glycolipid of *Mycobacterium kansasii*. Tetrahedron **1992**, *48*, 10133–10148.

- Zuurmond, H. M.; Veeneman, G. H.; van der Marel, G. A.; van Boom, J. H. Iodonium ion-assisted synthesis of a haptenic tetrasaccharide fragment corresponding to the inner cell-wall glycopeptidolipid of *Mycobacterium avium* serotype 4. Carbohydr. Res. 1993, 241, 153–164.
- 14. Lowary, T. L.; Hindsgaul, O. Recognition of synthetic *O*-methyl, epimeric and amino analogues of the acceptor α -L-Fuc*p*-(1 \rightarrow 2)- β -D-Gal*p*-OR by the blood-group A and B gene-specified glycosyltransferases. Carbohydr. Res. **1994**, *251*, 33–67.

Received March 19, 2001 Accepted September 26, 2001



Request Permission or Order Reprints Instantly!

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the <u>U.S. Copyright Office</u> for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on <u>Fair Use in the Classroom</u>.

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our <u>Website</u> User Agreement for more details.

Order now!

Reprints of this article can also be ordered at http://www.dekker.com/servlet/product/DOI/101081CAR100108285